1Q24 Investor Update

Collaboration Highlights Since March 2021, following a C$221 million strategic investment from BAT subsidiary, the partnership has gone from strength-to-streng th ● ● ● PRODUCT DEVELOPMENT COLLABORATION Organigram and BAT contributing complimentary capabilities and sharing a commitment to responsible category stewardship. The PDC continues to focus on the development of next generation products, adhering to the highest regulatory and compliance standards ● Significant achievements have materialized from a scientific development standpoint in terms of revenue driving product capability Organigram has benefitted from BAT's deep understanding of plant science and device and product technology BAT has gained substantial knowledge from Organigram with respect to the cannabis plant and product category The PDC is in late-stage development of a suite of emulsions, novel vapour formulations, flavour innovations, and packaging solutions which are to be applied across some products in Organigram's portfolio in calendar year 2024 For ingestible innovations, Organigram has completed pharmacokinetic (PK) studies to substantiate benefits of emulsification technologies and analysis of results is underway ORGANIGRAM BAT "PDC" A BETTER TOMORROW ORGANIGRAM Dedication to Research and Product Development 10

View entire presentation